News
Triple inhaler combo quells COPD exacerbations
A triple inhaler combination with 320 mcg of budesonide was associated with a significantly lower risk of all-cause mortality than a dual-drug...
News
Ibrutinib-venetoclax produces high MRD-negative rates in CLL/SLL
Minimal residual disease was undetectable in peripheral blood of 75% of patients after an ibrutinib lead-in and 12 cycles of the combination.
News
Pembrolizumab plus EP gives slight PFS edge in ES-SCLC
The KEYNOTE-604 trial showed a small progression-free survival benefit with the addition of pembrolizumab to standard chemotherapy.
News
Celecoxib ‘should not be used’ as adjuvant therapy for stage III colon cancer
Neither disease-free survival nor overall survival were improved by adding celecoxib to adjuvant FOLFOX chemotherapy.
News
Secondary surgery extends OS in recurrent ovarian cancer
Cytoreductive surgery provided a significant survival benefit over chemotherapy alone for patients with favorable presurgical predictive scores....
News
Oral relugolix works to a T against advanced prostate cancer
Compared with leuprolide, relugolix reduced testosterone levels more rapidly and was associated with a lower incidence of cardiovascular side...
News
Upfront pembrolizumab doubles PFS in MSI-H/dMMR metastatic colorectal cancer
Pembrolizumab outperformed chemotherapy in patients with microsatellite-instability high/mismatch repair-deficient metastatic colorectal cancer....
News
Pembrolizumab plus chemo shows benefits for PD-L1–rich triple-negative breast cancer
Patients with triple-negative breast cancers with PD-L1 combined positive score higher than 10 had better progression-free survival with...
News
Adjuvant osimertinib extends DFS in localized NSCLC
Osimertinib reduced the risk of disease recurrence or death by 79% in patients with EGFR-mutated non–small cell lung cancer.